Balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices.

Authors

Alia S Dadabhai, Thomas Jefferson UniversityFollow
Jonathan M Fenkel, Thomas Jefferson UniversityFollow
Daniel B Brown, Thomas Jefferson UniversityFollow
Loren Laine, Yale University School of Medicine and V.A. Connecticut Healthcare System

Document Type

Article

Publication Date

4-1-2012

Comments

This article has been peer reviewed. It is the authors' final version prior to publication in Hepatology

Volume 55, Issue 4, March 2012, Pages 1301-1304.

The published version is available at DOI: 10.1002/hep.25635. Copyright © John Wiley & Sons, Inc.

Abstract

Clinical Perspectives in Hepatology aims to engage two experts with opinions supporting differing perspectives on the management of a case. Typically, the case represents an area of debate or evolving practice in clinical hepatology.

The patient presented below gives us the opportunity to discuss balloon-occluded retrograde transvenous obliteration (BRTO) for treatment of gastric varices. Although described since the mid-1990s and accepted as effective therapy, particularly in Japan, BRTO is used sporadically in the United States and Europe. In fact, it is not mentioned in the U.S. (AASLD) or European (EASL/Baveno V) guidelines. Hopefully, increased awareness of and expertise in this modality will generate the evidence-based data needed to establish the role and safety of BRTO in patients with gastric varices.

Recommended Citation

Dadabhai, Alia S; Fenkel, Jonathan M; Brown, Daniel B; and Laine, Loren, "Balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices." (2012). Division of Gastroenterology and Hepatology Faculty Papers. Paper 8.
https://jdc.jefferson.edu/gastro_hepfp/8

PubMed ID

22318957